Cardiff Lexington Announces Third Quarter 2025 Financial Results
Cardiff Lexington (OTCQB:CDIX) reported third quarter results for the period ended September 30, 2025, showing substantial revenue and margin improvement versus the prior-year quarter.
- Total revenue rose 125.6% to $3.1 million (3Q24 included a one-time $1.7M accounting charge).
- Gross profit increased 437.8% to $1.9 million (62.4% margin).
- Income from continuing operations improved to $643,000 (21.0% of revenue).
- Non-GAAP adjusted EBITDA for Q3 was $663,000; year-to-date adjusted EBITDA was $1.9 million.
- Cash totaled $232,000 and total assets were $27.6 million.
Cardiff Lexington (OTCQB:CDIX) ha riportato i risultati del terzo trimestre per il periodo terminato il 30 settembre 2025, mostrando un notevole incremento di ricavi e margini rispetto al trimestre dell'anno precedente.
- Ricavi totali aumentati del 125,6% a $3,1 milioni (il 3Q24 includeva un onere contabile una tantum di 1,7 milioni di dollari).
- Utile lordo aumentato del 437,8% a $1,9 milioni (margine del 62,4%).
- Reddito da operazioni in corso migliorato a $643.000 (21,0% dei ricavi).
- Adj. EBITDA non-GAAP per il Q3 è stato di $663.000; EBITDA rettificato da inizio anno è stato di $1,9 milioni.
- Cassa ammontava a $232.000 e i total assets erano $27,6 milioni.
Cardiff Lexington (OTCQB:CDIX) presentó los resultados del tercer trimestre para el periodo terminado al 30 de septiembre de 2025, mostrando una mejora sustancial en ingresos y márgenes frente al trimestre del año anterior.
- Ingresos totales subieron un 125,6% a $3,1 millones (el 3T24 incluyó un cargo contable único de $1,7 millones).
- Utilidad bruta aumentó un 437,8% a $1,9 millones (margen del 62,4%).
- Ingresos de operaciones continuas mejoraron a $643.000 (21,0% de los ingresos).
- EBITDA ajustado no-GAAP para el 3T fue de $663.000; EBITDA ajustado acumulado de año fue de $1,9 millones.
- Efectivo totalizó $232.000 y los activos totales fueron $27,6 millones.
Cardiff Lexington (OTCQB:CDIX)는 2025년 9월 30일로 종료된 기간에 대한 3분기 실적을 발표했습니다. 전년 동기 대비 매출과 마진이 크게 개선되었습니다.
- 총매출은 125.6% 증가하여 $3.1백만이 되었으며(3Q24는 일회성 회계처리로 $1.7백만이 반영되었습니다).
- 총이익은 437.8% 증가하여 $1.9백만 (마진 62.4%)를 기록했습니다.
- 계속영업으로 인한 이익은 $643,000로 개선되었습니다(매출의 21.0%).
- 비GAAP 조정 EBITDA는 3분기에 $663,000였고, 연간 누적 조정 EBITDA는 $1.9백만였습니다.
- 현금은 $232,000이며 총자산은 $27.6백만였습니다.
Cardiff Lexington (OTCQB:CDIX) a publié ses résultats du troisième trimestre pour la période terminé le 30 septembre 2025, montrant une amélioration substantielle du chiffre d'affaires et des marges par rapport au trimestre de l'année précédente.
- Chiffre d'affaires total a augmenté de 125,6% pour atteindre $3,1 millions (le 3T24 comprenait une charge comptable unique de 1,7 million de dollars).
- Bénéfice brut a augmenté de 437,8% pour atteindre $1,9 millions (marge de 62,4%).
- Résultat des activités poursuivies s'est amélioré à $643,000 (21,0% du chiffre d'affaires).
- EBITDA ajusté non-GAAP pour le T3 était de $663,000; EBITDA ajusté cumulé depuis le début de l'année était de $1,9 millions.
- Liquidités s'élevaient à $232,000 et les actifs totaux s'élevaient à $27,6 millions.
Cardiff Lexington (OTCQB:CDIX) berichtete die Ergebnisse des dritten Quartals für den Zeitraum zum 30. September 2025 und verzeichnete eine deutliche Umsatz- und Margenverbesserung gegenüber dem Vorjahresquartal.
- Gesamtumsatz stieg um 125,6% auf $3,1 Millionen (das 3Q24 enthielt eine einmalige buchhalterische Belastung von 1,7 Mio. USD).
- Bruttogewinn erhöhte sich um 437,8% auf $1,9 Millionen (Bruttomarge 62,4%).
- Erträge aus Fortführungsgeschäften verbesserten sich auf $643.000 (21,0% der Umsätze).
- Non-GAAP bereinigtes EBITDA für Q3 betrug $663.000; kumuliertes EBITDA ab Jahrbeginn betrug $1,9 Millionen.
- Cash belief sich auf $232.000 und die Gesamtvermögenswerte betrugen $27,6 Millionen.
Cardiff Lexington (OTCQB:CDIX) أظهرت نتائج الربع الثالث للفترة المنتهية في 30 سبتمبر 2025، مع تحسن كبير في الإيرادات وهوامش الربح مقارنةً بالربع السابق.
- إجمالي الإيرادات ارتفع بنسبة 125.6% ليصل إلى $3.1 مليون (الربع الثالث لعام 2024 شمل حُمولة محاسبية لمرة واحدة قدرها 1.7 مليون دولار).
- الربح الإجمالي زاد بنسبة 437.8% إلى $1.9 مليون (هامش 62.4%).
- الدخل من العمليات المستمرة تحسن إلى $643,000 (21.0% من الإيرادات).
- EBITDA المعدل غير-GAAP للربع الثالث كان $663,000; EBITDA المعدل منذ بداية السنة كان $1.9 مليون.
- النقد بلغ $232,000 وكانت الأصول الإجمالية $27.6 مليون.
- Total revenue +125.6% to $3.1M in Q3 2025
- Gross profit +437.8% to $1.9M (62.4% margin)
- Income from continuing operations +209.9% to $643K (21.0% of revenue)
- YTD revenue +70.2% to $8.8M
- YTD adjusted EBITDA increased to $1.9M
- Net loss of $(1.1M) in Q3 2025
- YTD net loss of $(2.8M)
- Interest expense rose to $(1.8M) in Q3 and $(4.6M) YTD
- Cash balance limited at $232K as of September 30, 2025
125.6% increase in total revenue to$3.1 million compared to 3Q24437.8% increase in gross profit to$1.9 million compared to 3Q24209.9% increase in income from continuing operations to$643,000 compared to 3Q24
LEXINGTON, KY / ACCESS Newswire / November 14, 2025 / Cardiff Lexington Corporation (OTCQB:CDIX) today announced financial results for the third quarter ended September 30, 2025.
Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commented, "Rebounding from our one-time
Third Quarter 2025 Financial Results
Total revenue increased
The following third quarter 2024 results include the one-time adjustment to third quarter 2024 revenue.
Gross profit increased
Total operating expenses increased to
Income from continuing operations increased
Net loss in the third quarter of 2025 was
Non-GAAP adjusted EBITDA, which excludes interest expense and the change in accounting estimate of the billing realization rate recognized in third quarter 2024, was
During the three months ended June 30, 2025, as part of the Company's ongoing enhancements to internal controls over financial reporting, a detailed review of its interest expense-related cash flow classification was performed. As a result, the Company restated certain amounts within the condensed consolidated statement of cash flows for the nine months ended September 30, 2024. This was reclassified to correct the presentation of
Year-to-Date Financial Highlights
Total revenue increased
The following year-to-date 2024 results include the one-time adjustment to third quarter 2024 revenue.
Gross profit increased
Total operating expenses increased to
Operating income increased to
Net loss in the first nine months of 2025 was
Non-GAAP adjusted EBITDA, which excludes interest expense and the change in accounting estimate of the billing realization rate recognized in third quarter 2024, was
Balance Sheet
Cash totaled
Total assets increased
Conference Call
Cardiff Lexington will hold a conference call and webcast for investors today, November 14, 2025, at 9:00 a.m. Eastern Time.
Shareholders and interested parties may participate in the conference call by dialing (888) 506-0062 and international participants should dial (973) 528-0011 and use access code: 223050. The call and the accompanying slide deck will also be webcast at:
https://www.webcaster5.com/Webcast/Page/3131/53160
The conference call and slide deck may also be accessed via the Investor Relations page of the Company's website at https://investor.cardifflexington.com/overview/default.aspx. Please allow extra time prior to the call to visit the site.
An online archive of the webcast will be available on the Investor Relations page of the Company's website following the call at https://investor.cardifflexington.com/overview/default.aspx. A replay of the conference call will be available one hour after completion of the call until Friday, November 28, 2025, by dialing (877) 481-4010 and international participants should dial (919) 882-2331. All callers must use access code 53160 to access the replay.
-----
About Cardiff Lexington Corporation:
Cardiff Lexington Corporation (OTCQB: CDIX) is a targeted healthcare holding company dedicated to acquiring and building middle-market niche health care clinics, primarily in Orthopedics, Spine Care, and Pain Management. The Company's partnership-driven culture emphasizes service excellence, teamwork, accountability, and performance.
All current revenue is derived from Nova Ortho and Spine, LLC, which operates a network of regional specialty and ancillary orthopedic care centers across Florida and Georgia. These facilities provide traumatic injury patients with comprehensive diagnostic and surgical services, primary care evaluations, interventional pain management, and specialty consultations.
For more information on Cardiff Lexington Corporation, you may access the company's website at https://cardifflexington.com/
FORWARD LOOKING STATEMENT: This news release contains forward looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's business, the Company's liquidity position, the Company's ability to obtain new business, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur.
Use of Non-GAAP Financial Measures
Cardiff Lexington Corporation prepares its consolidated financial statements in accordance with United States generally accepted accounting principles ("GAAP"). In addition to GAAP disclosures, this document contains financial information and measures considered to be "non-GAAP". These non-GAAP measures can be used in order to gain a more complete and accurate understanding of the Company's financial condition and results. Non-GAAP financial measures should be considered in conjunction with, and not as a substitute to GAAP financial measures.
Cardiff Lexington Investor Relations
investorsrelations@cardifflexington.com
(800) 628-2100 ext. 705
or
IMS Investor Relations
cardifflexington@imsinvestorrelations.com
(203) 972-9200
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025, AND 2024
(Unaudited)
For the Three Months Ended | For the Nine Months Ended | |||||||||||||||
September 30, | September 30, | September 30, | September 30, | |||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Total revenue | $ | 3,058,740 | $ | 1,355,641 | $ | 8,763,314 | $ | 5,149,416 | ||||||||
Total cost of sales | 1,149,161 | 1,000,601 | 3,317,943 | 2,741,765 | ||||||||||||
Gross profit | 1,909,579 | 355,040 | 5,445,371 | 2,407,651 | ||||||||||||
Operating expenses | ||||||||||||||||
Depreciation expense | 762 | 3,365 | 4,890 | 10,096 | ||||||||||||
Loss on disposal of fixed assets | 0 | 0 | 12,593 | 0 | ||||||||||||
Stock compensation expense | 41,188 | 0 | 138,688 | 300,225 | ||||||||||||
Selling, general and administrative | 1,224,350 | 936,835 | 3,492,310 | 2,622,981 | ||||||||||||
Total operating expenses | 1,266,300 | 940,200 | 3,648,481 | 2,933,302 | ||||||||||||
Income (loss) from continuing operations | 643,279 | (585,160 | ) | 1,796,890 | (525,651 | ) | ||||||||||
Other (expense) income: | ||||||||||||||||
Other expense | (20,550 | ) | (6,767 | ) | (22,147 | ) | (4,720 | ) | ||||||||
Gain on debt refinance, forgiveness and settlement | 0 | 0 | 0 | 78,834 | ||||||||||||
Penalties and fees | (1,500 | ) | 0 | (1,500 | ) | (1,330 | ) | |||||||||
Interest expense | (1,765,528 | ) | (1,386,041 | ) | (4,594,714 | ) | (1,803,657 | ) | ||||||||
Amortization of debt discounts | 0 | 0 | 0 | (24,821 | ) | |||||||||||
Total other expense | (1,787,578 | ) | (1,392,808 | ) | (4,618,361 | ) | (1,755,694 | ) | ||||||||
Net loss before discontinued operations | (1,144,299 | ) | (1,977,968 | ) | (2,821,471 | ) | (2,281,345 | ) | ||||||||
Loss from discontinued operations | 0 | 0 | 0 | (111,312 | ) | |||||||||||
Net loss | $ | (1,144,299 | ) | $ | (1,977,968 | ) | $ | (2,821,471 | ) | $ | (2,392,657 | ) | ||||
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF SEPTEMBER 30, 2025, AND DECEMBER 31, 2024
(Unaudited)
September 30, | December 31, | |||||||
2025 | 2024 | |||||||
ASSETS | ||||||||
Current assets | ||||||||
Cash | $ | 232,033 | 1,188,185 | |||||
Accounts receivable-net | 20,699,999 | 15,934,490 | ||||||
Prepaid and other current assets | 112,514 | 89,901 | ||||||
Total current assets | 21,044,546 | 17,212,576 | ||||||
Property and equipment, net | 3,715 | 21,198 | ||||||
Land | 540,000 | 540,000 | ||||||
Goodwill | 5,666,608 | 5,666,608 | ||||||
Right of use - assets | 281,514 | 406,950 | ||||||
Due from related party | 4,979 | 4,979 | ||||||
Other assets | 68,154 | 73,368 | ||||||
Total assets | $ | 27,609,516 | 23,925,679 | |||||
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' (DEFICIT)/EQUITY | ||||||||
Current liabilities | ||||||||
Accounts payable and accrued expense | $ | 1,659,791 | 1,379,760 | |||||
Accrued expenses - related parties | 4,722,691 | 4,553,057 | ||||||
Accrued interest | 567,986 | 429,200 | ||||||
Right of use - liability | 214,002 | 223,330 | ||||||
Notes - current portion | 200,803 | 312,180 | ||||||
Line of credit | 14,727,190 | 8,645,991 | ||||||
Convertible notes payable, net of debt discounts of | 50,000 | 105,000 | ||||||
Net liabilities of discontinued operations | 238,285 | 238,285 | ||||||
Total current liabilities | 22,380,748 | 15,886,803 | ||||||
Other liabilities | ||||||||
Notes payable | 139,590 | 251,725 | ||||||
Operating lease liability - long term | 75,727 | 185,877 | ||||||
Total liabilities | 22,596,065 | 16,324,405 | ||||||
Mezzanine equity | ||||||||
Redeemable Series N Senior Convertible Preferred Stock - 3,000,000 shares authorized, | 3,680,194 | 3,339,317 | ||||||
Redeemable Series X Senior Convertible Preferred Stock - 5,000,000 shares authorized, | 1,697,687 | 1,576,788 | ||||||
Total Mezzanine Equity | 5,377,881 | 4,916,105 | ||||||
Stockholders' (deficit)/equity | ||||||||
Series B Preferred Stock - 3,000,000 shares authorized, | 0 | 5,119,468 | ||||||
Series C Preferred Stock - 500 shares authorized, | 0 | 296 | ||||||
Series E Preferred Stock - 1,000,000 shares authorized, | 0 | 701,500 | ||||||
Series F-1 Preferred Stock - 50,000 shares authorized, | 15,500 | 15,500 | ||||||
Series I Preferred Stock - 15,000,000 shares authorized, | 40,300,368 | 41,876,368 | ||||||
Series L Preferred Stock - 400,000 shares authorized, | 1,277,972 | 1,277,972 | ||||||
Series Y Senior Convertible Preferred Stock - 1,500,000 shares authorized, | 4,167,056 | 3,916,500 | ||||||
Common Stock: 300,000,000 shares authorized, | 19,905 | 15,300 | ||||||
Additional paid-in capital | 30,388,568 | 22,711,350 | ||||||
Accumulated deficit | (76,533,799 | ) | (72,949,085 | ) | ||||
Total stockholders' (deficit)/equity | (364,430 | ) | 2,685,169 | |||||
Total liabilities, mezzanine equity and stockholders' equity | $ | 27,609,516 | 23,925,679 | |||||
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025, AND 2024
(Unaudited)
The following table reconciles Net (loss) income before discontinued operations (a GAAP measure) to EBITDA (a non-GAAP measure)
For the Three Months Ended | For the Nine Months Ended | |||||||||||||||
September 30, | September 30, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
EBITDA (1) | ||||||||||||||||
Net loss before discontinued operations | $ | (1,144,299 | ) | $ | (1,977,968 | ) | $ | (2,821,471 | ) | $ | (2,281,345 | ) | ||||
Add: | ||||||||||||||||
Interest | 1,765,528 | 1,386,041 | 4,594,714 | 1,803,657 | ||||||||||||
Taxes | 0 | 0 | 0 | 0 | ||||||||||||
Depreciation | 762 | 3,365 | 4,890 | 10,096 | ||||||||||||
Amortization | 0 | 0 | 0 | 24,821 | ||||||||||||
EBITDA (1) | $ | 621,991 | $ | (588,562 | ) | $ | 1,778,133 | $ | (442,771 | ) | ||||||
Adjusted EBITDA (2) | ||||||||||||||||
EBITDA | $ | 621,991 | $ | (588,562 | ) | $ | 1,778,133 | $ | (442,771 | ) | ||||||
Add: | ||||||||||||||||
Change in estimate for settlement realization rate | 0 | 1,650,474 | 0 | 1,650,474 | ||||||||||||
Stock compensation expense for shares issued | 41,188 | 0 | 138,688 | 300,225 | ||||||||||||
Adjusted EBITDA (2) | $ | 663,179 | $ | 1,061,912 | $ | 1,916,821 | $ | 1,507,928 | ||||||||
(1) EBITDA is a non-GAAP financial measure defined as Earnings Before Interest, Income Tax, Depreciation and Amortization. | ||||||||||||||||
(2) Adjusted EBITDA is a non-GAAP financial measure that is the sum of EBITDA plus non-recurring and non-cash charges. | ||||||||||||||||
Adjusted EBITDA excluding other non-recurring costs (3) | ||||||||||||||||
Adjusted EBITDA | $ | 663,179 | $ | 1,061,912 | $ | 1,916,821 | $ | 1,507,928 | ||||||||
Add: | ||||||||||||||||
Scaling and restructuring costs for business growth | 0 | 76,110 | 11,676 | 180,302 | ||||||||||||
Acquisition related costs | 113,436 | 0 | 171,515 | 0 | ||||||||||||
Adjusted EBITDA excluding other non-recurring costs (3) | $ | 776,615 | $ | 1,138,022 | $ | 2,100,012 | $ | 1,688,230 | ||||||||
3) Adjusted EBITDA excluding other non-recurring costs is a non-GAAP financial measure that is the sum of Adjusted EBITDA plus other non-recurring costs.
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
RECONCILIATION OF REVENUE FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025, AND 2024
(Unaudited)
For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
GAAP Revenue | $ | 3,058,740 | $ | 1,355,641 | $ | 8,763,314 | $ | 5,149,416 | ||||||||
Adjustments to Claim Settlement Realization Rate | - | 1,650,474 | - | 2,849,629 | ||||||||||||
Non-GAAP Adjusted Revenue | $ | 3,058,740 | $ | 3,006,115 | $ | 8,763,314 | $ | 7,999,045 | ||||||||
SOURCE: Cardiff Lexington Corporation
View the original press release on ACCESS Newswire
FAQ
What were Cardiff Lexington (CDIX) Q3 2025 total revenue and growth rate?
How did Cardiff Lexington's gross margin change in Q3 2025 (CDIX)?
What was Cardiff Lexington's Q3 2025 income from continuing operations (CDIX)?
What is Cardiff Lexington's cash position and total assets as of September 30, 2025 (CDIX)?
How did interest expense affect Cardiff Lexington's results in 2025 (CDIX)?
When is Cardiff Lexington's investor conference call for the Q3 2025 results (CDIX)?
